| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | THRX | Common Stock | Purchase | $115K | +11.5K | +0.07% | $9.97 | 16.4M | Jan 19, 2022 | See Footnotes | F1, F2, F6 |
| transaction | THRX | Common Stock | Purchase | $348K | +35K | +0.21% | $9.95 | 16.4M | Jan 20, 2022 | See Footnotes | F2, F3, F6 |
| transaction | THRX | Common Stock | Purchase | $1.12M | +112K | +0.68% | $9.97 | 16.5M | Jan 21, 2022 | See Footnotes | F2, F4, F6 |
| holding | THRX | Common Stock | 499K | Jan 19, 2022 | See Footnotes | F5, F6 |
| Id | Content |
|---|---|
| F1 | These shares of the Issuer's common stock ("Shares") were purchased in a block order at price of $9.97. |
| F2 | The Shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. The Reporting Person is a member of OrbiMed Advisors. By virtue of such relationship, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII. |
| F3 | These Shares were purchased in a block order at price of $9.95. |
| F4 | Represents the weighted average purchase price of the Shares purchased ranging from a low of $9.495 to a high of $10.275 per Share. The Reporting Person undertakes, upon request by the Commission staff, the Issuer or a security holder of the Issuer, to provide full information regarding the number of Shares purchased at each separate price. |
| F5 | The shares are held of record by OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of OrbiMed Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationship, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OrbiMed Genesis. |
| F6 | Each of the Reporting Person, GP VII, Genesis GP, and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Person, GP VII, Genesis GP, or OrbiMed Advisors is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. |